We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Safety and Efficacy of Two Drug Regimens in Subjects With Moderate to Severe Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02065622
Recruitment Status : Recruiting
First Posted : February 19, 2014
Last Update Posted : October 11, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
To evaluate safety and efficacy of two dosing regimens in achieving clinical remission in subjects with moderately to severely active Ulcerative Colitis.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Drug: Adalimumab Other: Placebo Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 940 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Study Start Date : March 27, 2014
Estimated Primary Completion Date : May 15, 2019
Estimated Study Completion Date : May 15, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Adalimumab
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: Standard Induction Dose
Standard Induction Dose
Drug: Adalimumab
Other Name: Humira
Other: Placebo
Experimental: Higher Induction Dose
Higher Induction Dose
Drug: Adalimumab
Other Name: Humira
Active Comparator: Standard Maintenance Dose
Standard Maintenance Dose
Drug: Adalimumab
Other Name: Humira
Other: Placebo
Experimental: Higher Maintenance Dose
Higher Maintenance Dose
Drug: Adalimumab
Other Name: Humira
Other: Placebo
Experimental: Experimental Maintenance Dose
Experimental Maintenance Dose
Drug: Adalimumab
Other Name: Humira


Outcome Measures

Primary Outcome Measures :
  1. Proportion of subjects achieving clinical remission (per full Mayo Score) [ Time Frame: Week 8 ]
  2. Proportion of week 8 responders (per full Mayo Score) achieving clinical remission (per full Mayo score) [ Time Frame: week 52 ]

Secondary Outcome Measures :
  1. Proportion of Week 8 responders (per full Mayo Score) achieving endoscopic improvement (endoscopic subscore of 0 or 1) [ Time Frame: Week 52 ]
  2. Proportion of subjects achieving endoscopic improvement (endoscopic subscore of 0 or 1) [ Time Frame: week 8 ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Ulcerative Colitis (UC) for at least 90 days, confirmed by endoscopy during Screening period.
  • Active UC with Mayo Score of 6 to 12 points and endoscopy subscore of 2 to 3 despite concurrent or prior treatment with a full and adequate course, in the opinion of the Investigator, with oral corticosteroids or immunosuppressants or both.

Exclusion Criteria:

  • Subject with Crohn's disease (CD) or indeterminate colitis (IC).
  • Current diagnosis of fulminant colitis and/or toxic megacolon.
  • Subjects with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.
  • Chronic recurring infections or active Tuberculosis (TB).
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02065622


Contacts
Contact: AbbVie_Call Center 847-283-8955 abbvieclinicaltrials@abbvie.com

  Show 166 Study Locations
Sponsors and Collaborators
AbbVie
Investigators
Study Director: Jasmina Kalabic, MD AbbVie
More Information

Additional Information:
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT02065622     History of Changes
Other Study ID Numbers: M14-033
2013-001682-16 ( EudraCT Number )
First Posted: February 19, 2014    Key Record Dates
Last Update Posted: October 11, 2017
Last Verified: October 2017

Keywords provided by AbbVie:
Ulcerative Colitis

Additional relevant MeSH terms:
Colitis
Ulcer
Colitis, Ulcerative
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases
Adalimumab
Anti-Inflammatory Agents
Antirheumatic Agents